Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

Exelixis was downgraded from Strong Buy to Hold after cutting 2026 revenue guidance to $2.500–$2.550B and citing lowered 2026 outlook plus mixed clinical trial results for zanzalintinib + TECENTRIQ in mCRC. While Q2 2026 revenue rose to $628.7M, the program delivered an overall survival benefit but missed the non-liver metastases subgroup endpoint. With the FDA PDUFA date set for Dec 3, 2026, uncertainty around future sales growth drove the cautious stance.

Analysis

The immediate market reaction should be driven less by the current quarter and more by the reset in forward visibility. When a profitable oncology name loses confidence in its next-year growth path, the multiple usually compresses faster than the earnings estimate, because investors stop paying up for an asset they can no longer underwrite as a durable compounder.

The bigger second-order effect is that this weakens the investment case for the company’s pipeline as a replacement engine, not just a near-term add-on. A mixed late-stage readout in a program meant to extend the franchise increases the chance that physicians, payers, and partners treat the asset as incremental rather than category-defining, which pushes out any meaningful re-rating until there is broader confirmatory data. That also reduces optionality for adjacent oncology platforms competing for late-line colorectal cancer capital and BD attention; names with cleaner registrational paths should be comparatively favored.

Over the next 1-3 months, the key risk is that management tries to defend the growth bridge without enough independent evidence, which can create another leg down on guidance skepticism. Over 6-18 months, the question is whether the legacy cash engine can offset a slower pipeline than bulls assumed. The contrarian view is that the stock may already be pricing in a lot of disappointment: if the core business remains highly cash-generative, downside is more likely to be multiple compression than a balance-sheet event unless the next update shows further erosion.

The thesis would be falsified if the next guidance cycle stabilizes the 2026 runway or if additional clinical data broadens the addressable population enough to restore a credible launch curve. Absent that, this is more of a re-rating story than a one-day event.

Key Decisions for Investors

• Short EXEL on post-downgrade strength; prefer a 3-6 month put spread over outright short exposure because the downside is primarily multiple compression, not solvency risk. Risk/reward improves if the stock rallies into any analyst-driven bounce before the next earnings cycle.
• If already long EXEL, trim rather than liquidate and use covered calls into the December 2026 catalyst window. The stock can still monetize a cash-generative base, but the rerating premium tied to pipeline replacement looks impaired.
• Watch for a relative-value long in more de-risked oncology cash generators versus EXEL if the market broadly punishes late-stage biotech optionality. The trade works only if the next company update fails to repair growth visibility; otherwise cover quickly on restored guidance confidence.
• Set a thesis alert on the next revenue guide and any additional subgroup data release. If management does not reestablish a credible 2026 growth bridge, expect further multiple compression over the next 1-3 quarters.